EHEric Houdeau

Eric Houdeau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eric Houdeau has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Exposition orale aux nanoparticules de dioxyde de titane (TiO2) : du franchissement de l’épithélium buccal et intestinal au devenir et aux effets dans l’organisme

    by Sarah Bettini, Eric Houdeau

    As we are faced with the exponential use of nanomaterials in consumer products, including food, the consequences of daily exposure to nanoparticles at low doses set public health issues for humans. Among the different routes of exposure, the oral route remains the less documented, although nanomaterials are commonly used as food additives, or incorporated into packaging in contact with food or water, to provide their texturing and anti-microbial properties, or as simple colorant agents. The oral and gastrointestinal mucosa are the first regions in contact with the ingested nanoparticles. The latter cross these biological barriers, and distribute to the systemic compartment. Although differences exist between categories of nanoparticles, given differences in their physico-chemical properties, primary particle size and solubility, the example given in this review with titanium dioxide (TiO₂) is intended to illustrate oral toxicity studies conducted in vivo and in vitro in order to contribute to the risk assessment in humans.


  • Open Access

    Changes in Intestinal Glucocorticoid Sensitivity in Early Life Shape the Risk of Epithelial Barrier Defect in Maternal-Deprived Rats

    by Nabila Moussaoui, Viorica Braniste, Afifa Ait-Belgnaoui, Mélissa Gabanou, Soraya Sekkal, Maiwenn Olier, Vassilia Théodorou, Pascal G. P. Martin, Eric Houdeau

    Glucocorticoids (GC) contribute to human intestine ontogeny and accelerate gut barrier development in preparation to birth. Rat gut is immature at birth, and high intestinal GC sensitivity during the first two weeks of life resembles that of premature infants. This makes suckling rats a model to investigate postpartum impact of maternal separation (MS)-associated GC release in preterm babies, and whether GC sensitivity may shape MS effects in immature gut. A 4 hours-MS applied once at postnatal day (PND)10 enhanced plasma corticosterone in male and female pups, increased by two times the total in vivo intestinal permeability (IP) to oral FITC-Dextran 4 kDa (FD4) immediately after the end of MS, and induced bacterial translocation (BT) to liver and spleen. Ussing chamber experiments demonstrated a 2-fold increase of permeability to FD4 in the colon immediately after the end of MS, but not in the ileum. Colonic permeability was not only increased for FD4 but also to intact horseradish peroxidase 44 kDa in MS pups. In vivo, the glucocorticoid receptor (GR) antagonist RU486 or ML7 blockade of myosin light chain kinase controlling epithelial cytoskeleton contraction prevented MS-induced IP increase to oral FD4 and BT. In addition, the GR agonist dexamethasone dose-dependently mimicked MS-increase of IP to oral FD4. In contrast, MS effects on IP to oral FD4 and BT were absent at PND20, a model for full-term infant, characterized by a marked drop of IP to FD4 in response to dexamethasone, and decreased GR expression in the colon only compared to PND10 pups. These results show that high intestinal GC responsiveness in a rat model of prematurity defines a vulnerable window for a post-delivery MS, evoking immediate disruption of epithelial integrity in the large intestine, and increasing susceptibility to macromolecule passage and bacteremia.


  • P075 Modulation du microbiote intestinale par un probiotique (Probio'Stick®) : impact sur l’activité cérébrale dans un modèle de stress chronique

    by A. Ait-Belgnaoui, A. Colon, V. Braniste, L. Ramalho, C. Rolland, C. Cartier, E. Houdeau, T. Tompkins, V. Theodorou

  • Open Access

    A Low Dose of Fermented Soy Germ Alleviates Gut Barrier Injury, Hyperalgesia and Faecal Protease Activity in a Rat Model of Inflammatory Bowel Disease

    by Lara Moussa, Valérie Bézirard, Christel Salvador-Cartier, Valérie Bacquié, Corinne Lencina, Mathilde Lévêque, Viorica Braniste, Sandrine Ménard, Vassilia Théodorou, Eric Houdeau

    Pro-inflammatory cytokines like macrophage migration inhibitory factor (MIF), IL-1β and TNF-α predominate in inflammatory bowel diseases (IBD) and TNBS colitis. Increased levels of serine proteases activating protease-activated receptor 2 (PAR-2) are found in the lumen and colonic tissue of IBD patients. PAR-2 activity and pro-inflammatory cytokines impair epithelial barrier, facilitating the uptake of luminal aggressors that perpetuate inflammation and visceral pain. Soy extracts contain phytoestrogens (isoflavones) and serine protease inhibitors namely Bowman-Birk Inhibitors (BBI). Since estrogens exhibit anti-inflammatory and epithelial barrier enhancing properties, and that a BBI concentrate improves ulcerative colitis, we aimed to evaluate if a fermented soy germ extract (FSG) with standardized isoflavone profile and stable BBI content exert cumulative or synergistic protection based on protease inhibition and estrogen receptor (ER)-ligand activity in colitic rats. Female rats received orally for 15 d either vehicle or FSG with or without an ER antagonist ICI 182.780 before TNBS intracolonic instillation. Macroscopic and microscopic damages, myeloperoxidase activity, cytokine levels, intestinal paracellular permeability, visceral sensitivity, faecal proteolytic activity and PAR-2 expression were assessed 24 h, 3 d and 5 d post-TNBS. FSG treatment improved the severity of colitis, by decreasing the TNBS-induced rise in gut permeability, visceral sensitivity, faecal proteolytic activity and PAR-2 expression at all post-TNBS points. All FSG effects were reversed by the ICI 182.780 except the decrease in faecal proteolytic activity and PAR-2 expression. In conclusion, the anti-inflammatory properties of FSG treatment result from two distinct but synergic pathways i.e an ER-ligand and a PAR-2 mediated pathway, providing rationale for potential use as adjuvant therapy in IBD.


  • Bisphenol A in the Gut: Another Break in the Wall?

    by Viorica Braniste, Marc Audebert, Daniel Zalko, Eric Houdeau


  • Impact of oral bisphenol A at reference doses on intestinal barrier function and sex differences after perinatal exposure in rats

    by Viorica Braniste, Aurore Jouault, Eric Gaultier, Arnaud Polizzi, Claire Buisson-Brenac, Mathilde Leveque, Pascal G. Martin, Vassilia Theodorou, Jean Fioramonti, Eric Houdeau

    Bisphenol A (BPA), a chemical estrogen widely used in the food-packaging industry and baby bottles, is recovered in human fluids (0.1–10 nM). Recent studies have reported that BPA is hormonally active at low doses, emphasizing the debate of a risk for human health. Estrogen receptors are expressed in the colon, and although the major route of BPA exposure is food, the effects on gut have received no attention. We first examined the endocrine disrupting potency of BPA on colonic paracellular permeability (CPP), experimental colitis, and visceral sensitivity in ovariectomized rats orally exposed to 5 mg/kg/d BPA (i.e., the no observed adverse effect level), 50 μg/kg/d BPA (i.e., tolerable daily intake), or lower doses. BPA dose-dependently decreased basal CPP, with a half-maximal inhibitory dose of 5.2 μg/kg/d, 10-fold below the tolerable daily intake. This correlated with an increase in epithelial tight junction sealing, also observed in Caco-2 cells exposed to 10 nM BPA. When ovariectomized rats were fed with BPA at the no observed adverse effect level, the severity of colitis was reduced, whereas the same dose increased pain sensitivity to colorectal stimuli. We then examined the impact of perinatal exposure to BPA on intestinal permeability and inflammatory response in the offspring. In female rats, but not in male rats, perinatal BPA evoked a decrease of CPP in adulthood, whereas the proinflammatory response of colonic mucosa was strengthened. This study first demonstrates that the xenoestrogen BPA at reference doses influences intestinal barrier function and gut nociception. Moreover, perinatal exposure promotes the development of severe inflammation in adult female offspring only.


  • Open Access

    Oestradiol decreases colonic permeability through oestrogen receptor β‐mediated up‐regulation of occludin and junctional adhesion molecule‐A in epithelial cells

    by Viorica Braniste, Mathilde Leveque, Claire Buisson‐Brenac, Lionel Bueno, Jean Fioramonti, Eric Houdeau

    Oestradiol modulates paracellular permeability and tight junction (TJ) function in endothelia and reproductive tissues, but whether the ovarian hormones and cycle affect the paracellular pathway in the intestinal epithelium remains unclear. Oestrogen receptors (ERs) are expressed in intestinal epithelial cells, and oestradiol regulates epithelium formation. We examined the effects of oestrous cycle stage, oestradiol benzoate (EB), and progesterone (P) on colonic paracellular permeability (CPP) in the female rat, and whether EB affects expression of the TJ proteins in the rat colon and the human colon cell line Caco‐2. In cyclic rats, CPP was determined through lumen‐to‐blood 51Cr‐labelled EDTA clearance, and in Ussing chambers for dextran permeability. CPP was also examined in ovariectomized (OVX) rats treated with P or EB, with and without the ER antagonist ICI 182,780, or with the selective agonists for ERα (propyl pyrazole triol; PPT) or ERβ (diarylpropionitrile; DPN). In oestrus rats, CPP was reduced (P < 0.01) relative to dioestrus. In OVX rats, EB dose‐dependently decreased CPP, an effect mimicked by DPN and blocked by ICI 182,780, whereas P had no effect. Oestradiol increased occludin mRNA and protein in the colon (P < 0.05), but not zona occludens (ZO)‐1. Further, EB and DPN enhanced occludin and junctional adhesion molecule (JAM)‐A expression in Caco‐2 cells without change in ZO‐1, an effect blocked by ICI 182,780. These data show that oestrogen reinforces intestinal epithelial barrier through ERβ‐mediated up‐regulation of the transmembrane proteins occludin and JAM‐A determining paracellular spaces. These findings highlight the importance of the ERβ pathway in the control of colonic paracellular transport and mucosal homeostasis.


  • Sex Steroid Regulation of Macrophage Migration Inhibitory Factor in Normal and Inflamed Colon in the Female Rat

    by Eric Houdeau, Raphael Moriez, Mathilde Leveque, Christel Salvador–Cartier, Aurelie Waget, Lin Leng, Lionel Bueno, Richard Bucala, Jean Fioramonti